States Take Unusual Actions To Control On-Label Drug Supply Amidst COVID-19 Shortages
Sixteen US states have issued executive orders or other mandatory directives to preserve hydroxychloroquine and chloroquine for non-COVID-19 patients, while 26 states have issued similar voluntary guidance. The federal government is reserving some of the strategic national stockpile supply of the drugs for non-COVID-19, as private players in the supply chain also join in the efforts to balance on-label use with COVID-related demand.
You may also be interested in...
Trump’s Big Bet On COVID-19 Vaccines May Have Shortchanged Therapeutics. Should Biden Rectify The Difference?
Incoming US President may be wise to up government investment in COVID-19 therapeutics, including both research and manufacturing, experts say. Additional government funding should target a larger variety of treatment types and prioritize better study designs.
How US FDA And Industry Are Looking To Navigate New Supply Chain Data Reporting Requirements
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.
Dexamethasone COVID-19 Findings Leave Authorities Bracing for Yet Another Demand Surge
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.